OncLive Staff

Articles

Johnson Previews the Potential Utility of VS-6766 Plus Defactinib in KRAS+ NSCLC

October 25th 2021

Dr. Johnson discusses the mechanism of action of VS-6766 alone and in combination with defactinib, expectations for the ongoing phase 2 RAMP 202 trial in KRAS-mutant non–small cell lung cancer, and where the combination could be used in practice pending further positive study results.

Abid on Optimizing COVID-19 Vaccines in CAR T-Cell Therapy Recipients

October 21st 2021

Dr. Abid discusses immune-compromising factors that are indigenous to CAR T-cell therapy recipients, the immunogenic potential of different COVID-19 vaccines, determinants of vaccine responses, and the potential need for booster vaccine dosing in this population.

Ilson Delves Into the Development of Checkpoint Inhibition in Gastric/GEJ Cancers

October 18th 2021

Dr. Ilson discusses treatment sequencing for patients with gastric and gastroesophageal junction cancer, the integration of immunotherapy into the frontline setting, and key ongoing studies in the field.

Gordan on Growing the Infrastructure for In-House Genomic Testing

October 14th 2021

Dr. Gordan discusses the advantages of in-house genomic testing, the transition from external to internal sequencing, and the anticipated effects of the move.

DeNunzio Describes the Advantages of Proton Beam Therapy in Oncology

October 11th 2021

Dr. DeNunzio discusses how proton beam therapy is being used throughout oncology, the advantages of the modality and how it complements other treatment interventions, and where research with the therapy is headed.

Moore Voices Excitement With VS-6766 Plus Defactinib in Ovarian Cancer

October 7th 2021

Dr. Moore discusses the basis for studying the combination of VS-6766 and defactinib in recurrent low-grade serous ovarian cancer, data that has been generated with the combination from the phase 1/2 FRAME trial, and the potential role for the combination in clinical practice.

Enfortumab Vedotin Challenges Standard of Care in Urothelial Carcinoma

October 5th 2021

Two indications have been granted by the FDA to the Nectin-4directed antibody, enfortumab vedotin-ejfv, marking a shift in the treatment landscape for patients with advanced urothelial carcinoma.

FDA Approval Insights: Amivantamab and Mobocertinib in EGFR Exon 20 Insertion+ NSCLC

October 4th 2021

Dr. Patel discusses the role of biomarker testing in lung cancer, the FDA approvals of amivantamab and mobocertinib in EGFR exon 20 insertion–positive NSCLC, and future research directions in this subset of lung cancer.

Genomically Guided Radiation Dosing in Oncology: Ready for Prime Time?

September 30th 2021

Dr. Scott and Dr. Torres-Roca discuss their research of a pooled retrospective analysis exploring genomic-adjusted radiation dose–based radiation therapy in solid tumors and what using genomics to guide radiation dosing decisions could mean for oncology practices.

Aggarwal and Girard Analyze Data Amassed With Durvalumab in Unresectable Stage III NSCLC

September 27th 2021

Dr. Aggarwal and Dr. Girard discuss the significance of the 5-year survival data from the pivotal PACIFIC trial and the real-world benefit of the study regimen in patients with unresectable stage III non–small cell lung cancer.

Monk Talks Tisotumab Vedotin and Exciting ESMO Data in Cervical Cancer

September 23rd 2021

Dr. Monk discusses the significance of the FDA approval of tisotumab vedotin and notable research that was presented at the 2021 ESMO Congress in cervical cancer.

Dietrich Details Data and Future Research With Immunotherapy in Stage III NSCLC

September 20th 2021

Dr. Dietrich discusses the latest developments with immunotherapy and targeted therapy in stage III non–small cell lung cancer.

Neel on Maximizing Research Strides in Oncology

September 16th 2021

Dr. Neel discusses the momentum of molecularly-driven research and treatment strategies in oncology, the continuation of current research trends, and potential future directions throughout the field.

Updates and Advances in the Treatment of Metastatic HER2+ Breast Cancer

September 14th 2021

Dr Pegram and colleagues focus on key clinical trials such as DESTINY-Breast01, HER2CLIMB, NALA, and SOPHIA in the setting of advanced HER2-positive breast cancer and discuss the practical considerations of these data.

Management of Early-Stage HER2-Positive Breast Cancer

September 14th 2021

In the second segment, Dr Pegram and colleagues discuss the clinical implications of the data from select trials in the neoadjuvant and adjuvant settings for patients with HER2-positive breast cancer.

Challenges and Unmet Needs in the Treatment of HER2-Positive Breast Cancer

September 14th 2021

In the first segment, Dr Pegram and colleagues highlight some of the challenges and remaining unmet needs in the management of patients with HER2-positive breast cancer.

Loaiza-Bonilla Offers Guidance on Optimizing Treatment Selection in Pancreatic Cancer

September 13th 2021

Dr. Loaiza-Bonilla discusses approaches to frontline treatment selection in metastatic pancreatic cancer, the effects of adverse effects and toxicities in treatment planning, and treatment options available to patients post gemcitabine-based regimens.

Lisberg Discusses the Promise of Datapotamab Deruxtecan in Lung Cancer

September 9th 2021

Lisberg discusses the excitement with datopotamab deruxtecan in non–small cell lung cancer and previews anticipated data from the NSCLC cohort of the TROPION-PanTumor01 trial at the International Association for the Study of Lung Cancer 2021 World Conference on Lung Cancer.

McKay Filters Through Frontline Treatment Considerations in mRCC

September 6th 2021

Dr. McKay discusses the importance of patient selection in advanced renal cell carcinoma, selecting between available combination regimens, and nuances regarding the timing of treatment in this disease.

Pirtobrutinib Exhibits Promising Efficacy in Heavily Pretreated MCL and Other Non-Hodgkin Lymphomas

September 3rd 2021

Pirtobrutinib elicited encouraging responses across all dose levels in patients with mantle cell lymphoma and other non-Hodgkin lymphoma who previously received all classes of available therapy, with benefit observed independent of prior therapy received, according to data from the phase 1/2 BRUIN study.